$NTRA

Sheena Jonathan sold $837K of NTRA

Sheena Jonathan sold 3,150 shares of Natera, Inc. (NTRA) at an average of $265.68 ($262.72–$268.39, $0.84M total) across 6 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jul 16, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may monitor for patterns in insider activity, but this specific disclosure lacks new fundamentals and is unlikely to drive a durable repricing by itself.

02

Market read

A disclosed insider sale by a director under a 10b5-1 plan, with no accompanying company-specific news.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it quantify total insider ownership changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed after-hours on 2026-07-15, covering sales dated 2026-07-13.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc., reported by a director and executed as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about 3,150 shares in an open-market sale totaling $836,898.26 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new guidance, contracts, or regulatory developments.

Market effects

Minimal. No sector-wide read-across is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the transaction may reflect scheduled liquidity needs rather than bearish expectations, so any negative tape reaction could be overdone.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Sheena Jonathan

    Director who sold shares totaling $836,898.26 across six trades on 2026-07-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.